4 In this issue of The Lancet Oncology, another phase 2 trial conducted exclusively in China with a different HER2-targeted antibody–drug conjugate as the palliative second-line treatment of NSCLC is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback